Glypican 3 overexpression in primary and metastatic Wilms tumors

详细信息    查看全文

• 作者：Maria Tretiakova ; Debra L. Zynger ; Chunyan Luan ; Nicole K. Andeen…
• 关键词：Glypican 3 ; GPC3 ; Wilms tumor
• 刊名：Virchows Archiv
• 出版年：2015
• 出版时间：January 2015
• 年：2015
• 卷：466
• 期：1
• 页码：67-76
• 全文大小：1,999 KB
• 参考文献：1. Hartwig S, Hu MC, Cella C, Piscione T, Filmus J, Rosenblum ND (2005) Glypican-3 modulates inhibitory BMP2-Smad signaling to control renal development in vivo. Mech Dev 122(7-):928-38 CrossRef
  2. White GR, Kelsey AM, Varley JM, Birch JM (2002) Somatic glypican 3 (GPC3) mutations in Wilms-tumour. Br J Cancer 86(12):1920-922 CrossRef
  3. Hughes-Benzie RM, Hunter AG, Allanson JE, Mackenzie AE (1992) Simpson-Golabi-Behmel syndrome associated with renal dysplasia and embryonal tumor: localization of the gene to Xqcen-q21. Am J Med Genet 43(1-):428-35 CrossRef
  4. Iglesias BV, Centeno G, Pascuccelli H, Ward F, Peters MG, Filmus J et al (2008) Expression pattern of glypican-3 (GPC3) during human embryonic and fetal development. Histol Histopathol 23(11):1333-340
  5. Pilia G, Hughes-Benzie RM, MacKenzie A, Baybayan P, Chen EY, Huber R et al (1996) Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet 12(3):241-47 CrossRef
  6. Saikali Z, Sinnett D (2000) Expression of glypican 3 (GPC3) in embryonal tumors. Int J Cancer 89(5):418-22 CrossRef
  7. Toretsky JA, Zitomersky NL, Eskenazi AE, Voigt RW, Strauch ED, Sun CC et al (2001) Glypican-3 expression in Wilms tumor and hepatoblastoma. J Pediatr Hematol Oncol 23(8):496-99 CrossRef
  8. Gillan TL, Hughes R, Godbout R, Grundy PE (2003) The Simpson-Golabi-Behmel gene, GPC3, is not involved in sporadic Wilms tumorigenesis. Am J Med Genet A 122A(1):30-6 CrossRef
  9. Takahashi M, Yang XJ, Sugimura J, Backdahl J, Tretiakova M, Qian CN et al (2003) Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene 22(43):6810-818 CrossRef
  10. Baumhoer D, Tornillo L, Stadlmann S, Roncalli M, Diamantis EK, Terracciano LM (2008) Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol 129(6):899-06 CrossRef
  11. Neri G, Marini R, Cappa M, Borrelli P, Opitz JM (1988) Simpson-Golabi-Behmel syndrome: an X-linked encephalo-tropho-schisis syndrome. Am J Med Genet 30(1-):287-99 CrossRef
  12. Opitz JM, Herrmann J, Gilbert EF, Matalon R (1988) Simpson-Golabi-Behmel syndrome: follow-up of the Michigan family. Am J Med Genet 30(1-):301-08 CrossRef
  13. Veugelers M, Cat BD, Muyldermans SY, Reekmans G, Delande N, Frints S et al (2000) Mutational analysis of the GPC3/GPC4 glypican gene cluster on Xq26 in patients with Simpson-Golabi-Behmel syndrome: identification of loss-of-function mutations in the GPC3 gene. Hum Mol Genet 9(9):1321-328 CrossRef
  14. Li M, Shuman C, Fei YL, Cutiongco E, Bender HA, Stevens C et al (2001) GPC3 mutation analysis in a spectrum of patients with overgrowth expands the phenotype of Simpson-Golabi-Behmel syndrome. Am J Med Genet 102(2):161-68 CrossRef
  15. Filmus J (2001) Glypicans in growth control and cancer. Glycobiology 11(3):19R-3R CrossRef
  16. De Cat B, David G (2001) Developmental roles of the glypicans. Semin Cell Dev Biol 12(2):117-25 CrossRef
  17. Khan
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Pathology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-2307

文摘

Glypican 3 (GPC3), a heparan sulfate proteoglycan, plays a role in cell growth and differentiation. Mutations of the GPC3 gene are responsible for Simpson-Golabi-Behmel syndrome, which is characterized by anomalies of postnatal overgrowth and an increased risk of developing pediatric malignancies, mostly Wilms tumor and liver cancer. In order to understand the possible role of GPC3 in renal development and Wilms tumor formation, we analyzed messenger RNA (mRNA) and protein levels of GPC3 in sporadic Wilms tumors and compared it to normal kidneys and other common renal epithelial tumors. By using Affymetrix HGU133 oligonucleotide gene expression microarray data from 191 renal tumors and 12 normal kidneys, we found significant overexpression of GPC3 in Wilms tumors (p--.01), with 3.5-fold higher expression in comparison to normal kidneys and 6.5-fold higher than any type of renal tumors. The GPC3 gene product in Wilms tumor was further evaluated by immunohistochemistry and quantified by an automated image analysis. Cytoplasmic and membranous GPC3 immunoreactivity was present in 77?% of primary Wilms tumors (23/30), 93?% of metastatic Wilms tumors (13/14), 50?% of metanephric adenomas (4/8), 33?% of congenital mesoblastic nephromas (2/6), 100?% of nephrogenic rests (11/11), and 100?% of fetal kidneys (5/5). GPC3 staining was predominantly identified in blastemal and epithelial components of Wilms tumors, similar to that of fetal non-neoplastic kidney. All adult renal tumors (n--0) and normal kidneys (n--5) were GPC3 negative. These findings suggest the utility of GPC3 in differential diagnosis and follow-up of Wilms tumors. Our data also indicate that GPC3 is an oncofetal protein with a potential therapeutic value.